Inter-method variability in bone alkaline phosphatase measurement: clinical impact on the management of dialysis patients.

  title={Inter-method variability in bone alkaline phosphatase measurement: clinical impact on the management of dialysis patients.},
  author={Etienne Cavalier and J. -C. Souberbielle and Romy Gadisseur and B. Dubois and Jean Marie Krzesinski and Pierre Delanaye},
  journal={Clinical biochemistry},
  volume={47 13-14},

Figures and Tables from this paper

Comparison between bone alkaline phosphatase immunoassay and electrophoresis technique in hemodialysis patients.
Although immunoassays are increasingly used, as fully automated methods, in a large number of laboratories and become routine methods for bALP determination, it should be beared in mind, also the heterogeneity of the b ALP itself, especially in patients on hemodialysis.
Variations of parathyroid hormone and bone biomarkers are concordant only after a long term follow-up in hemodialyzed patients
A concordance between ΔPTH and Δbone biomarkers is observed in dialysis patients, but only after a long follow-up, and should be based on serial assessments of biomarkers, rather than scattered values.
Analytical evaluation of the Nittobo Medical tartrate resistant acid phosphatase isoform 5b (TRACP-5b) EIA and comparison with IDS iSYS in different clinically defined populations
Nittobo TRACP-5b presents interesting analytical features and a good concordance with IDS iSYS and these methods could thus potentially be harmonized.
Does PTH Offer Additive Value to ALP Measurement in Assessing CKD-MBD?
The role of PTH in driving increased bone turnover has long been appreciated but measurement of P TH was initially hindered in renal patients by non-specificity of available radioimmunoassays which detected retained biologically inactive C-terminal fragments of the hormone.
Clinical usefulness of bone turnover marker concentrations in osteoporosis.
Clinical Inference of Serum and Bone Sclerostin Levels in Patients with End-Stage Kidney Disease
The unique combined evaluation of bone sclerostin expression, bone histomorphometry, bone biomarkers, and serum sclerOSTin levels, as assessed by 4 different assays demonstrated that sclerastin may qualify as a clinically relevant marker of disturbed bone metabolism in ESKD patients.
Title : Clinical usefulness of bone turnover marker levels in osteoporosis Corresponding
It is possible that knowledge derived from clinical studies can further enhance fracture risk estimation tools with inclusion of BTM together with other independent risk factors as well as physiological and pre-analytical factors contributing to variability in BTM concentrations are required.
Considerations in parathyroid hormone testing
From the post-analytical perspective, establishment of reliable reference ranges requires further efforts as the selection criteria for reference subjects should take into consideration new variables such as gender, race and vitamin D levels.


Bone-specific alkaline phosphatase concentrations are less variable than those of parathyroid hormone in stable hemodialysis patients
This study provides further support for the use of bone ALP as an alternative marker of bone mineral metabolism in the setting of chronic kidney disease–mineral and bone disorder.
Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients.
Plasma bAP level equal or higher than 20 ng/mL, either alone or combined with plasma iPTH of 200 pg/ mL, had the highest sensitivity, specificity, and predictability values for the diagnosis of high-turnover bone disease, and formally excluded patients with normal or LTBD.
Inter-method variability in PTH measurement: implication for the care of CKD patients.
Important inter-method variability in PTH results is found owing to both antibody specificity and standardization reasons, and it is proposed to use assay-specific decision limits for CKD patients, or to apply a correcting factor to the P TH results obtained with a given assay.
Can we use circulating biomarkers to monitor bone turnover in CKD haemodialysis patients? Hypotheses and facts.
The strengths and limitations of the now recommended biomarkers, i.e. parathormone and bone-specific alkaline phosphatase, and some of the most promising, but still not recommended, emerging biomarkers are discussed.
Bone alkaline phosphatase in CKD-mineral bone disorder.
The overall merits of bone ALP as a marker of bone turnover in adults with CKD-MBD are considered, published bone histomorphometric data comparing bone ALP to PTH are examined, and possible pathogenic mechanisms by which bone ALP may be linked to outcomes in patients with CKd are discussed.
Low bone turnover in patients with renal failure.
It is found that bone strontium levels were increased in patients with osteomalacia as compared to all other types of ROD, and evidence for a causal role of the element in the development of a mineralization defect could be tested experimentally by adding strontum to drinking water in a chronic renal failure rat model.
Can we use circulating biomarkers to monitor bone turnover in CKD haemodialysis patients
  • Hypotheses and facts. Nephrol Dial Transplant
  • 2014
Bone alkaline phosphatase (BAP): a biochemical marker of bone turnover; 2013 [13-11-2013.Ref Type: Internet Communication
  • 2013
Variability of new bone mineral metabolism markers in patients treated with maintenance hemodialysis: implications for clinical decision making.